At a glance
ClinicalIndex Comparison RecordPhase 2Active· 72 enrolled
Drug / intervention
Dinaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma
In Brief
A Phase 2 clinical trial evaluating Dinaciclib for Acral Lentiginous Melanoma and 6 related conditions. Active but no longer recruiting, targeting 72 participants across 190 sites.
Detailed Summary
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma, Mucosal Melanoma, Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionOct 2013
TodayJul 2026
Study CompletionMar 2027
First PostedJul 13, 2009
Enrollment StartJul 1, 2009
Primary CompletionOct 22, 2013
Study CompletionMar 19, 2027
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.0 years ago
Interventions
Dinaciclibdrug
Given IV